117 related articles for article (PubMed ID: 22221098)
1. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
[TBL] [Abstract][Full Text] [Related]
2. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Montaldo PG; Gambini C; Allen TM; Bogenmann E; Ponzoni M
Int J Cancer; 2003 May; 104(5):559-67. PubMed ID: 12594810
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
7. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
8. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.
Raffaghello L; Pagnan G; Pastorino F; Cosimo E; Brignole C; Marimpietri D; Bogenmann E; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):151-5. PubMed ID: 12880975
[TBL] [Abstract][Full Text] [Related]
9. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.
Ponzoni M; Bocca P; Chiesa V; Decensi A; Pistoia V; Raffaghello L; Rozzo C; Montaldo PG
Cancer Res; 1995 Feb; 55(4):853-61. PubMed ID: 7850799
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts.
Ponthan F; Lindskog M; Karnehed N; Castro J; Kogner P
Oncol Rep; 2003; 10(5):1587-92. PubMed ID: 12883745
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antitumor activity of the novel derivatized polyvinyl alcohol-based polymer P10(4).
Raffaghello L; Zuccari G; Carosio R; Orienti I; Montaldo PG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3485-93. PubMed ID: 16740774
[TBL] [Abstract][Full Text] [Related]
14. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
15. Improvement of aqueous solubility of fenretinide and other hydrophobic anti-tumor drugs by complexation with amphiphilic dextrins.
Orienti I; Zuccari G; Carosio R; Montaldo PG
Drug Deliv; 2009 Oct; 16(7):389-98. PubMed ID: 19624248
[TBL] [Abstract][Full Text] [Related]
16. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
17. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
19. Mixed micelles of TPGS and Soluplus
Wang Y; Ding Y; Xu Y; Wang C; Ding Y; Gao M; Ma C; Ma X; Li L
Pharm Dev Technol; 2020 Sep; 25(7):865-873. PubMed ID: 32266855
[TBL] [Abstract][Full Text] [Related]
20. Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles.
Okuda T; Kawakami S; Higuchi Y; Satoh T; Oka Y; Yokoyama M; Yamashita F; Hashida M
Int J Pharm; 2009 May; 373(1-2):100-6. PubMed ID: 19429294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
